👏 Proud to share our CEO & co-founder @nabihasaklayen served as a judge for @techreview’s 2026 Innovators Under 35. Congrats to this year’s honorees advancing #science, #biotech & #innovation! Meet the innovators below ⬇️ technologyreview.com/superto…

What would it take for AI to compress decades of scientific progress into years, and make that progress open, verifiable, and widely shared? In just a few weeks, some of the best minds working on this are joining us for a 2-day workshop in San Francisco. Speakers include: • @soniaarrison, @100Plus Capital • @tomoxl, @synchroninc • @MartinBJensen, @GordianBio • @dileeplearning, @AsteraInstitute • @MollyminHe, @ElemBio • @nabihasaklayen, @CellinoBio • @mikhailshapiro, @Caltech • @elidourado, @AsteraInstitute • Sean Escola, @protocollabs • @Alexteng, @fiftyyears • @draparente, @CivilizationVC • @beccajcarlson, @deliverome • @Ben_Reinhardt, @Spec__Tech • @vivnat, @GoogleDeepMind This workshop is part of our AI Node program in the Bay Area. Participants can stay and sprint at our SF Node for a few weeks afterward to keep building in community. If you’re researching or building at the intersection of AI and scientific discovery, apply to attend. Link in first reply.

🧬 In 2006, a breakthrough in #Kyoto changed how we think about what a cell can become. @nabihasaklayen shares how Dr. Shinya Yamanaka’s lab discovered four factors that can reprogram adult cells into #iPSCs, a powerful cell state with many possibilities. piped.video/watch?v=1s5PtsMo…

Two Physicists Walk Into a Stem Cell Lab... 🔬 Our Co-Founders @NabihaSaklayen & @MadridMarinna reflect on their journey from #physics to #biology, the idea behind @CellinoBio & why they’re excited about the next chapter of #iPSCs. ▶️ Watch below! piped.video/wAQ-0L8vbdc?si=hMk0…

20 years after the discovery of #iPSCs, Nobel Laureate Dr. Shinya Yamanaka discusses how his lab is advancing #iPSC therapies toward the clinic, the possibilities of CRISPR and organoids, and the future of #regenmed. Listen below ⬇️ stemcellpodcast.com/ep-327-t…

We're excited to be part of the 10th Annual @startupBOSorg Week! 🚀 Join our Chief of Staff & Head of Strategy, @Becky_Kusko, on Sept. 16 as she shares practical insights from her experience leading strategy and business development across the #biotech industry. 👉 Register: startupbos.org/sbw2026

Excited to join the global #StemCell community at #ISSCR2026. We're proud to support the @ISSCR Board of Directors & Invited Speakers Reception and look forward to several days of scientific discussions, collaboration, and bold ideas! 🚀🧬

Our CEO & Co-Founder, @nabihasaklayen, will speak at @foresightinst's AI for Frontier & Meta Science Workshop in #SanFrancisco, Sept. 28–30. Nabiha will speak on "Cellular Reprogramming Is a Manufacturing Problem." Details: bit.ly/4fnJ3fQ

🏆 What a memorable evening in #NYC at @FastCompany’s 2026 Most Innovative Companies Gala and Summit! We’re honored to have @CellinoBio recognized alongside innovators advancing breakthrough technologies with real-world impact. Read more about #FCMostInnovative here: fastcompany.com/most-innovat…

Every milestone that improves scalability and consistency in #regenmed brings us closer to making personalized therapies accessible to more #patients. Learn more about our work on the ARPA-H NEBULA program alongside Polyphron below ⬇️

🗓️ Join @nabsicle, our CEO & Co-Founder, at @LongevityGL’s Aging Code Summit during #BOSTechWeek on May 26 at 1:30 PM ET to discuss #AI’s role in #AgingResearch. 👉 Use code CELLINOGUEST50 at longevitygl.org/boston.

🧬 @CellinoBio is building automated, closed, #AI-driven systems to address one of #biotech’s key challenges: scaling #celltherapy manufacturing. Hear how from our CEO, @nabsicle, on @GalaxyBalanceHQ with host Cory Smith. 🎧 Listen now: piped.video/bGPViuR2cnw

While AI is mostly being used for drug discovery, we are limited by how we manufacture it. In this episode of Galaxy Balance, I sit down with Nabiha Saklayen, CEO of @CellinoBio, to explore one of the biggest bottlenecks in biotech. Manufacturing. Cell therapies are already here. The science works. But turning them into something that can reach millions of people is still unsolved. Nabiha is building a new paradigm. Closed, automated, AI-driven systems that treat biology more like semiconductors than hand-crafted experiments. We go deep into iPSCs, variability, automation, and what it actually takes to move from a breakthrough in the lab to a therapy in a patient. We also explore how physics thinking reshapes biology, why autologous therapies may still win long term, and what happens when AI fully enters the lab. This is a conversation about scale, precision, and the infrastructure required to engineer the future of medicine. Full episode in the comments. #Biotech #CellTherapy #SyntheticBiology #AI #Longevity #Bioengineering #GalaxyBalance

📄 A new publication from @theNASEM Forum highlights how #AI is advancing #RegenMed, from improving trial design to scalable manufacturing. Featuring contributions from @nabsicle, our CEO, who serves as a #RegenMedForum Member. Check out the publication here: nationalacademies.org/units/…

🧬 Join us next month at #SynBioBeta2026 as our Co-Founder & CEO, @nabsicle, speaks on “Epigenetics and Stem Cells Reprogramming / Evidence Based Longevity” on May 7 at 3:30 PM PDT. We can’t wait to see you in #SanJose! Register now: syntheticbiologysummit.com

When Dr. Nabiha Saklayen (CEO-@CellinoBio) joined us on Episode 13, her core argument was not just that personalized cell therapies were scientifically exciting, but that manufacturing was the real bottleneck. Cellino’s bet was that laser-based, AI-guided cell handling could turn autologous therapies from bespoke lab work into something much closer to an industrial process. Last week, Cellino posted a meaningful translation update: new results from its collaboration with Polyphron, with four iPSC lines from diverse donors manufactured on its platform. For a company built around making autologous cell therapies actually scalable, this is the kind of milestone that matters. That is why the post stood out. It is one thing to talk abstractly about regenerative medicine at scale. It is another to show diverse donor lines moving through a foundry-style system designed for reproducibility. The episode is still a useful listen if you want the original framing for what Cellino was trying to build: not another cell therapy company, but infrastructure for making personalized cell therapies manufacturable. 🎧 Ep 13: • Apple: lnkd.in/g8y4f4YH • Spotify: lnkd.in/gMAMBufM

🔬 Headed to the 2026 @nova_aging conference? Our CEO @nabsicle will join the mainstage for the “Repair and Regeneration Panel” on April 25 in #Boston, discussing new approaches to treating age-related #neurologicalconditions. Register: novaneuro.org

Excited to share a closer look at the first results from our collaboration with Polyphron! @CellinoBio manufactured four #iPSC lines from diverse donors and engineered them into structurally equivalent cortical tissue by Polyphron's foundry. 📄 Access the white paper: bit.ly/4mc5Vk8 👉 Read the full release: bit.ly/41SarLm

The foundry is alive!!! We just released results from our collaboration with Polyphron. Four iPSC lines from diverse donors, manufactured by @CellinoBio, were engineered into structurally equivalent cortical tissue by Polyphron's foundry. Under 90 days from kickoff to data!! Watching another rockstar team take our cells and run with them is one of the best feelings. Huge congratulations to @FabioZB_I, @thematthewosman, and the Polyphron team. And Catherine Pilsmaker on our team, for leading! white paper: polyphron.com/post/closing-t…

Very exciting results from our collaboration with @CellinoBio! We manufactured iPSC lines from four genetically diverse donors and engineered them into structurally equivalent cortical tissue, without re-optimizing the platform for each new genotype. This is the first demonstration we are aware of where a computational optimization layer has been used to transfer morphogenetic perturbation knowledge across iPSC donor lines, rather than relying on protocol standardization or brute-force re-screening. The core problem: iPSC lines from different patients behave differently. Everyone in the field knows this. The same differentiation protocol applied to four donors produced up to 9x variance in our structural readout. This is one of the reasons patient-specific tissue manufacturing has never scaled. The standard fix is to run a full optimization screen for every new donor line. That's hundreds of experiments per genotype. It works in a single-patient academic study. It does not work if you're trying to manufacture tissue for a real population or get population scale data from perturbing tissue. Our approach: learn the structure of inter-donor variability computationally. We mapped perturbation trajectories across data-rich donor lines, then transferred those trajectories to new lines using minimal anchor data from the target genotype. Result: 19 of 20 top-performing conditions across all four donors matched the alignment values of our fully optimized reference line. The two most molecularly divergent donors converged on the highest alignment. The platform reduced the experimental footprint for new donors by 12x. Cellino's automated iPSC manufacturing is what makes this possible upstream. If your cell manufacturing process introduces uncontrolled technical variability, you can't distinguish it from biological variability. You need both problems solved simultaneously, and that's what this collaboration demonstrates. We also ran bulk and single-cell RNA-seq across all four lines. The donors were spread across two major axes of transcriptomic variation: epigenetic repression state and progenitor-to-neuronal commitment bias. These are not similar lines. The platform worked anyway. We've previously shown the foundry generalizes across tissue contexts (cortical to cardiac). Now we've shown it generalizes across donors within a tissue context. No architectural changes to the platform. The same system handles both axes of variation. The program took <90 days to spin up and complete. It was awesome working with @nabsicle & the Cellino team - more to come! Link to whitepaper in thread.